HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

August 2nd 2021

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Dr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer

July 29th 2021

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.

KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer

July 28th 2021

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment Algorithm

July 26th 2021

William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

July 22nd 2021

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer

July 16th 2021

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12th 2021

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

HER2 Positivity at Diagnosis Shows Better PFS Benefit With HER2-Based Therapies Vs Negative Status in Breast Cancer

July 12th 2021

The median progression-free survival benefit experienced by patients with metastatic breast cancer who were HER2 positive at initial diagnosis and who were receiving standard HER2-directed therapies proved to be more favorable than what was reported in those who were HER2 negative and switched to HER2 positive status.

Tucatinib Detectable in CSF of HER2+ Metastatic Breast Cancer With Leptomeningeal Disease

July 12th 2021

Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.

Dr. Carey on the Clinical Implications of the FeDeriCa trial in HER2+ Breast Cancer

July 8th 2021

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

FDA Approves Dose-Escalation Label Update for Neratinib in HER2+ Breast Cancer

July 1st 2021

The FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent in patients with HER2-positive breast cancer, as examined in the phase 2 CONTROL trial, and the new 133-count commercial Nerlynx SKU.

Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal Disease

June 29th 2021

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Dr. Wei on the Potential Implications of the CompassHER2 RD Trial in HER2+ Breast Cancer

June 15th 2021

Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

eMonarcHER to Examine Abemaciclib Plus Adjuvant Endocrine Therapy in HER2+ Early Breast Cancer

June 14th 2021

The safety and efficacy of abemaciclib will be examined in patients with hormone receptor–positive, HER2-positive, node-positive, high-risk early breast cancer who have completed standard adjuvant HER2-targeted treatment as part of the phase 3 eMonarcHER trial.

Frontline Trastuzumab Deruxtecan Under Exploration With or Without Pertuzumab in HER2+ Breast Cancer

June 14th 2021

Fam-trastuzumab deruxtecan-nxki is under investigation with or without pertuzumab vs a standard-of-care regimen comprised of a taxane, trastuzumab, and pertuzumab in the frontline treatment of patients with HER2-positive metastatic breast cancer as part of the phase 3 DESTINY-Breast09 trial.

Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer

June 8th 2021

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer

June 6th 2021

The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer

June 6th 2021

Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.

Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer

June 5th 2021

Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.

Dr. Powell on Remaining Questions With Interstitial Lung Disease in HER2+ Breast Cancer

June 3rd 2021

Charles Powell, MD, MBA, discusses remaining questions with interstitial lung disease in HER2-positive breast cancer.